Drug-Induced CYP2D6 Phenoconversion Among Individuals with a Psychiatric Disorder: Prevalence and Association with Psychological Distress

Background/Objectives: Phenoconversion extends pharmacogenomics beyond genetic variation by accounting for non-genetic factors that can also dynamically alter metabolism, influence treatment response, adverse effect risk and overall patient outcomes. CYP2D6 phenoconversion is problematic in people with psychiatric conditions due to the high comorbidity and polypharmacy burden in this population and the significant proportion of psychiatric medications that inhibit CYP2D6 metabolism or are directly metabolised by CYP2D6. Our aim was to estimate the prevalence of CYP2D6 phenoconversion, the association with comorbidity and polypharmacy and the impact on mental health outcomes.